EGETIS THERAPEUTICS

Year-End report January-December 2023

Egetis achieved several significant milestones during the fourth quarter of 2023

- **Submitted marketing authorisation application for Emcitate® (tiratricol) for the treatment of MCT8 deficiency to the European Medicines Agency EMA**
- **Secured MSEK 462 in combined financing, consisting of a private placement of MSEK 172, at a premium, and a debt financing of MSEK 290**
- **Entered into an exclusive licensing agreement with Fujimoto to develop and commercialize Emcitate® in Japan**
- **The ReTRIACt study is progressing with 10 patients included**

Financial overview October-December

- Quarterly revenue MSEK 32.6 (5.7), of which MSEK 14.5 (-) was a milestone payment for a licensing agreement in Japan
- Quarterly loss MSEK -86.3 (-77.8)
- Cash at the end of the quarter amounted to MSEK 303.3 (127.7)
- Cash flow for the quarter was MSEK 223.6 (-62.8)
- Earnings per share before/after dilution SEK -0.3 (-0.4)

Financial overview January-December

- Revenue for the period MSEK 57.6 (22.6), of which MSEK 14.5 (-) was a milestone payment for a licensing agreement in Japan
- Net loss for the period MSEK -326.9 (-193.8)
- Cash at the end of the period amounted to MSEK 303.3 (127.7)
- Cash flow for the period MSEK 180.4 (-19.5)
- Earnings per share before/after dilution SEK -1.3 (-1.0)

Significant events during the quarter

- Secured approximately MSEK 462 in a combined financing comprising a MSEK 172 equity private placement, at a premium, and MSEK 290 debt financing (MEUR 25)
- Delivered a drawdown notice to BlackRock for the drawdown of Tranche A (MEUR 10) of the Debt Financing
- Recruited Desiree Luthman as Vice President Global Regulatory Affairs and Laetitia Szaller as Legal Counsel and Head of Compliance
- Organized an investor day on December 19, 2023 (a link to the investor day can be found here)

Emcitate® (tiratricol)

- Submitted marketing authorisation application (MAA) for *Emcitate* for the treatment of MCT8 deficiency to the EMA, which was subsequently verified on October 26
- Entered into an exclusive licensing agreement with Fujimoto to develop and commercialize *Emcitate* in Japan
- Provided updates on the Expanded Access Program for *Emcitate* in the USA

Significant events after the quarter

- In total, 10 (out of a target of 16 evaluable) patients have been included for the ReTRIACt study, which is pivotal for the US submission

Financial overview

	2023 Oct-Dec	2022 Oct-Dec	2023 Jan-Dec	2022 Jan-Dec
Net revenue, MSEK	32.6	5.7	57.6	22.6
Result after tax, MSEK	-86.3	-77.8	-326.9	-193.8
Cash flow, MSEK	223.6	-62.8	180.4	-19.5
Cash, MSEK	303.3	127.7	303.3	127.7
Equity ratio	72%	90%	72%	90%
Earnings per share, SEK	-0.3	-0.4	-1.3	-1.0
Earnings per share after dilution, SEK	-0.3	-0.4	-1.3	-1.0
Average number of employees	30	15	27	15

Comments from the CEO

2023 was a year of strong progress for Egetis and to make our lead investigational drug *Emcitate* (tiratricol) available to patients in need. While the first half of the year saw an unsolicited approach from external parties regarding a potential acquisition of the Company, the second half of 2023 provided several important milestones. In July, the first patients were included in the ReTRIACt study, which is pivotal in the USA. In October, the Company submitted a marketing authorisation application (MAA) for *Emcitate* for the treatment of MCT8 deficiency to the European Medicines Agency (EMA), and shortly thereafter, Egetis secured approximately 462 million SEK in combined financing, consisting of a directed new share issue of 172 million SEK (gross), at a premium to the closing price of the day, and a debt financing of approximately 290 million SEK (MEUR 25). Our largest shareholder is now specialist investor Frazier Life Sciences from California, USA, which has a track record of partnerships with scientifically driven companies in the healthcare sector.

In November, the Company entered into an exclusive licensing agreement with Fujimoto to develop and commercialize *Emcitate* in Japan.

Egetis submitted marketing authorisation application for *Emcitate* for the treatment of MCT8 deficiency to the EMA

On October 9, we submitted our MAA for *Emcitate* for the treatment of MCT8 deficiency to the EMA. On October 27, we announced that the MAA had been validated and is under formal review by the Committee for Medicinal Products for Human Use (CHMP) at the EMA. The average duration of the review process for MAAs at EMA is approximately 13-14 months.

Two new hospitals have been included in the ReTRIACt study, which is pivotal in the USA

Following an agreement with the FDA, Egetis is conducting a confirmatory, randomized, placebo-controlled study (ReTRIACt) in 16 evaluable patients to verify the results from previous clinical trials and publications regarding the normalization of thyroid hormone T3 levels, to support the submission of a New Drug Application (NDA) in the USA. The first patients were included in the ReTRIACt study in July, at Erasmus Medical Center in Rotterdam, The Netherlands, and Children's Hospital of Philadelphia, USA. Recently, two additional hospitals have been included in the study. Addenbrooke's Hospital in Cambridge, UK, began recruiting patients in mid-December, and Saint Louis University Hospital in St. Louis, Missouri, USA, started recruiting patients in

January 2024. As of February 22, 2024, a total of 10 patients had been included in the study. As previously communicated, the Company will update the market once recruitment is completed, and at that time provide information on when to expect topline results and subsequently when the NDA is expected to be submitted.
More information about the ReTRIACt study is available on clinicaltrials.gov under the code NCT05579327.

Egetis entered into an exclusive licensing agreement with Fujimoto to develop and commercialize *Emcitate* in Japan

Egetis entered into an exclusive licensing agreement with Fujimoto Pharmaceutical Corporation in November to develop and commercialize *Emcitate* in Japan. According to the terms of the agreement, Fujimoto has been granted exclusive rights for the development and commercialization of *Emcitate* for the treatment of MCT8 deficiency in Japan. Fujimoto will pay upfront, development, and regulatory milestones totaling JPY 600 million (approximately SEK 45 million). Egetis will supply the product in semi-finished form and receive approximately one-third of the applicable income from Fujimoto. Fujimoto will also finance the development program required for *Emcitate* in Japan, which will be clarified after discussions with the Pharmaceuticals and Medical Devices Agency (PMDA). As the future holder of the marketing authorization in Japan, Fujimoto will be responsible for regulatory interactions with PMDA.

Egetis continued to increase awareness of MCT8 deficiency

MCT8 deficiency is an ultra-rare genetic disease first described in 2004, and there are currently no approved therapies for this disease. Consequently, the general awareness of the disease and the diagnosis are very low, even among specialist physicians, and a large portion of patients remain misdiagnosed. Egetis' medical affairs activities are focused on improving awareness of the disease and its diagnosis, by participation and dialogues at scientific conferences, creating patient identification partnerships with genetic testing companies, engaging with Key Opinion Leaders, advisory committees, and interactions with patient groups. This has resulted in an additional 50 patients being identified with MCT8 deficiency in the USA who were previously undiagnosed. More information about MCT8 deficiency is available at www.mct8deficiency.com.

Emcitate is available to qualifying patients through Egetis' Expanded Access Program in the USA

At the request of the FDA, Egetis has implemented an Expanded Access Program (EAP) in the USA. Currently, 12 hospitals have requested participation in this program. The EAP program for *Emcitate* facilitates physicians in accessing the medication for their MCT8 deficiency patients who are ineligible for a clinical trial until the product receives market authorization. The program is also important for patients who complete the ReTRIACt study so that they can continue treatment with *Emcitate* after completing the study. There is continued significant and growing interest from physicians worldwide in treating patients with MCT8 deficiency with *Emcitate*, which is already being prescribed as part of Managed Access Programs to patients in over 25 countries. Currently around 200 patients are being treated with *Emcitate*, and more patients are gaining access to treatment, a true validation of the significant medical need for these patients.

Triac Trial II with *Emcitate*

Triac Trial II is an ongoing international, open-label, multicenter study in young patients (<30 months old) with MCT8 deficiency. The recruitment target was achieved in the second quarter of 2022, with 22 patients included. The study is being conducted in Europe and the USA and examines the neurocognitive effects of early intervention with *Emcitate*, as well as the effect on clinical and biochemical aspects of thyrotoxicosis. Patients are initially treated with *Emcitate* for 96 weeks and then followed for an

additional two years. Results from the study are expected in mid-2024. The design of the Triac Trial II study is available on clinicaltrials.gov under the code NCT02396459.

The pivotal Albatross study for Aladote® (calmangafodipir)

The pivotal phase IIb/III study (Albatross) with *Aladote* to reduce the risk of acute liver injury associated with paracetamol (acetaminophen) overdose has been designed in consultation with the regulatory authorities FDA, EMA, and MHRA. The start of the study has been postponed until *Emcitate* marketing authorization submissions for MCT8 deficiency have been completed.

Egetis continues to attract and recruit highly experienced colleagues

In November Desiree Luthman was recruited as Vice President Global Regulatory Affairs. Desiree has over 25 years of experience in the pharmaceutical industry in Global Regulatory Affairs and has successfully contributed to obtaining both FDA and EMA approvals for new drugs. Before joining Egetis, Desiree was Senior Vice President Regulatory Affairs at Passage Bio, a US gene therapy company. Previously, she held senior positions at Verona Pharma, Sanofi, BMS, Celgene, Xytis, and AstraZeneca.
In December Laetitia Szaller was recruited as General Counsel and Head of Compliance. Laetitia has over 17 years of experience in the pharmaceutical sector. She holds dual qualifications to practice law in both the UK and Belgium. Before joining Egetis, Laetitia was General Counsel and VP Business Development at AM-Pharma in the Netherlands and was a member of the company's management team. Prior to that, Laetitia worked at UCB, Abbott, and Zoetis.

An Investor Day was held on December 19, 2023

On December 19, 2023, Egetis hosted an investor day in Stockholm. The investor day included presentations by Dr. Andrew Bauer from Children's Hospital of Philadelphia on MCT8 deficiency and the unmet medical need, as well as by Dr. Carla Moran from University College Dublin on a separate indication called resistance to thyroid hormone beta (RTH-beta) and the unmet medical need in this disease. Members of Egetis' management team highlighted the significant progress made by Egetis towards potential market approvals for *Emcitate*, including a status update on the ReTRIACt study, as well as plans for preparatory activities and commercialization focusing on disease awareness, market access, and value proposition. Furthermore, the Company's strategic goals in the short and long term were presented. (Link to the Investor Day)

Cash

We reported cash of approximately SEK 303 million as of December 31, 2023. In addition, we have access to an additional debt financing totaling EUR 15 million, which will be available provided that the Company meets certain conditions, including those related to the Phase III ReTRIACt study for *Emcitate*.

Outlook

I look forward to 2024 to be a transformational year for Egetis. Our employees are focused on delivering five key milestones:

1. Complete the ReTRIACt study, which is pivotal in the USA, as soon as possible
2. Results from the Triac Trial II study in mid-2024
3. Thriving towards a potential positive opinion from EMA for *Emcitate* for MCT8 deficiency
4. Preparatory launch activities in Europe
5. Preparing the NDA for *Emcitate* in the USA

Nicklas Westerholm, CEO

About Egetis Therapeutics

Egetis Therapeutics is an innovative and integrated pharmaceutical company, focusing on projects in late-stage development for commercialization for treatments of serious diseases with significant unmet medical needs in the orphan drug segment.

The Company's lead drug candidate *Emcitate* is under development for the treatment of patients with monocarboxylate transporter 8 (MCT8) deficiency, a highly debilitating rare disease with no available treatment. In previous studies (Triac Trial I and a long-term real-life study) *Emcitate* has shown highly significant and clinically relevant results on serum thyroid hormone T3 levels and secondary clinical endpoints. Egetis submitted a marketing authorisation application (MAA) for *Emcitate* to the European Medicines Agency (EMA) in October 2023.

After a dialogue with the FDA, Egetis is conducting a randomized, placebo-controlled pivotal study in 16 patients to verify the results on T3 levels seen in previous clinical trials and publications. Egetis will update the market as soon as recruitment has been completed and at that point inform about the timing of availability of top-line results, and the expected timing of the subsequent NDA filing.

Emcitate holds Orphan Drug Designation (ODD) for MCT8 deficiency and resistance to thyroid hormone type beta (RTH-beta) in the US and the EU. MCT8 deficiency and RTH-beta are two distinct indications, with no overlap in patient populations. *Emcitate* has been granted Rare Pediatric Disease Designation (RPDD) which gives Egetis the opportunity to receive a Priority Review Voucher (PRV) in the US, after approval. This voucher can be transferred or sold to another sponsor.

The drug candidate *Aladote* is a first in class drug candidate developed to reduce the risk of acute liver injury associated with paracetamol (acetaminophen) overdose. A proof of principle study has been successfully completed. The design of a pivotal Phase IIb/III study (Albatross), with the purpose of applying for market approval in the US and Europe, has been finalized following interactions with the FDA, EMA and MHRA. The study start has been postponed until *Emcitate* marketing authorization submissions for MCT8 deficiency have been completed. *Aladote* has been granted ODD in the US and in the EU.

Egetis Therapeutics (STO: EGTX) is listed on the Nasdaq Stockholm main market. For more information, see www.egetis.com

Pipeline overview



Project updates

Emcitate

Events during the quarter

- Submitted marketing authorisation application (MAA) for *Emcitate* for the treatment of MCT8 deficiency to the EMA, which EMA verified on October 26
- Entered into an exclusive licensing agreement with Fujimoto to develop and commercialize *Emcitate* in Japan
- Provided updates on disease awareness and patient education initiatives
- Provided update on the Expanded Access Program for *Emcitate* in the USA

Events after the quarter

- In total, 10 (out of a target of 16 evaluable) patients have been included for the ReTRIACt study, which is pivotal for the submission in the USA

About *Emcitate*

Emcitate is Egetis' lead drug candidate in clinical development. It addresses monocarboxylate transporter 8 (MCT8) deficiency, also known as Allan-Herndon-Dudley Syndrome (AHDS), a rare genetic disease that affects 1 in 70,000 men with high unmet medical need with no available treatment.

Thyroid hormones are crucial for the development and metabolic state of virtually all tissues. Thyroid hormone transport across the plasma membrane is required for the hormones' metabolism and intracellular action and is facilitated by thyroid hormone transporters, including MCT8. Mutations in the gene for MCT8 cause MCT8 deficiency. The gene is located on the X chromosome and therefore mainly affects men, as men only have one X chromosome.

The resulting dysfunction of MCT8 leads to impaired transport of thyroid hormone into certain cells and across the blood-brain-barrier and disruption of normal thyroid hormone regulation. Patients with MCT8 deficiency therefore have low concentrations of thyroid hormone in the central nervous system, which signals that the body should produce more thyroid hormone. This leads to increased levels of active thyroid hormone T3 in peripheral tissues, also called thyrotoxicosis. This leads to a complex pattern of symptoms with neurological developmental delay and intellectual disability, accompanied by severely elevated circulating thyroid hormone concentrations which are toxic for tissues including the heart, muscle, liver and kidney and results in symptoms such as failure to thrive, cardiovascular stress, insomnia and muscle wasting.

Most patients will never develop the ability to walk or even sit independently. At present there is no approved therapy available for the treatment of MCT8 deficiency.

Emcitate was granted Orphan Drug Designation in the EU in 2017 and the US in 2019. *Emcitate* received US Rare Paediatric Disease Designation (RPDD) in 2020. Upon approval of the NDA, sponsors holding a RPDD and meeting the criteria specified can apply to receive a Priority Review Voucher (PRV). A PRV provides accelerated FDA review of a subsequent new drug application for any drug candidate, in any indication, shortening time to market in the US. The voucher may also be sold or transferred to another sponsor. During the last few years PRVs have been sold for around $100 million.

A Phase IIb clinical trial (Triac Trial I) in MCT8 deficiency has been completed which showed significant and clinically relevant treatment effects on key aspects of the disease. In October 2021, strong data from long-term treatment in patients with MCT8 deficiency up to 6 years, with *Emcitate* was published in the *Journal of Clinical Endocrinology & Metabolism*. The data comes from an investigator-initiated real-life cohort study at 33 sites conducted by the Erasmus Medical Center, Rotterdam, The Netherlands, where

the efficacy and safety of *Emcitate* was investigated in 67 patients with MCT8 deficiency.

Based on the new long-term data in 2021, Egetis had further interactions with the regulatory agencies in the US and Europe. In December 2021, the EMA concluded that the clinical data from the Triac Trial I, together with the published data from long-term treatment, is sufficient for a regulatory submission of a Marketing Authorisation Application (MAA) to the EMA for the treatment of MCT8 deficiency and Egetis has successfully completed the submission on October 9, 2023. The average review time for MAAs is generally 13-14 months.

FDA acknowledges that a treatment effect on T3 levels and the manifestations of chronic thyrotoxicosis in MCT8- deficiency could provide a basis for marketing approval also in the US. Egetis is conducting a randomized study in 16 patients for up to 30 days to verify the T3 results, seen in previous clinical trials and publications. The design of this study (ReTRIACt) is available on clinicaltrials.gov under the code NCT055793. It is well established that the T3 levels in untreated MCT8 patients are significantly elevated, and we have previously shown that *Emcitate* is able to normalize these levels rapidly and durably. As of February 22, 2024, a total of 10 patients had been included in the study. Egetis will update the market as soon as recruitment has been completed and at that point inform about the timing of availability of top-line results, and the expected timing of the subsequent NDA filing.

The ongoing Triac Trial II study included 22 young boys with MCT8 deficiency (<30 months old) and is investigating the neurocognitive effects of early intervention with *Emcitate*. Results are expected in mid-2024.

Emcitate is already supplied to around 200 patients in Managed Access Programs, following individual regulatory approvals from national regulatory agencies in over 25 countries, The most recent program to open is the EAP in the USA, requested by the FDA. Managed Access Programs allow early access to a medicine prior to regulatory marketing approval, granted to pharmaceuticals under development for conditions with high unmet medical needs and where no available treatment alternatives exist.

Emcitate has been granted orphan drug designation (ODD) for RTH-β in the USA and the EU. RTH-β is an additional indication, without overlap in patient populations, to the previously obtained ODD for MCT8 deficiency. The ODD for RTH-β is a direct result of Egetis' work to extend the indications for the *Emcitate* program to related but distinct conditions.

Aladote

No events during the quarter

About *Aladote*

Aladote is a first-in-class drug candidate with the potential to reduce the risk of acute liver failure associated with paracetamol/acetaminophen poisoning. *Aladote* has shown a beneficial effect in relevant preclinical models, even in the time-window when N-acetylcysteine (NAC) treatment no longer is effective (>8 hours). A proof of principle study in patients with paracetamol poisoning to prevent acute liver injury has been successfully completed. The study results provide preliminary evidence of the safety and tolerability of the combination of Aladote and NAC. Further, the results indicate that Aladote may reduce acute liver injury in this patient population.

Aladote has been granted Orphan Drug Designation (ODD) in the US and EU.

Paracetamol/acetaminophen is the most used drug in the world for the treatment of fever and pain, but also one of the most overdosed drugs – intentionally or unintentionally. Paracetamol overdose is one of the most common methods in suicide attempts. When excessive amounts of paracetamol are metabolized in the liver, the harmful metabolite N-acetyl-p-benzoquinone imine (NAPQI) is formed, which can cause acute liver failure. The current standard of care for paracetamol poisoning, NAC, is effective if the patient receives medical care within eight hours of ingestion.

A pivotal Phase IIb/III study, Albatross, will be targeting patients with increased risk of liver injury, who arrive late at hospital, more than eight hours after a paracetamol overdose, for which current standard of care, NAC, is substantially less effective. Study start is planned after *Emcitate* marketing authorization submissions for MCT8 deficiency have been completed.

Financial Information

Year-End report January – December 2023

Revenue and results

Revenue

Revenue amounted to MSEK 32.6 (5.7) during the quarter and MSEK 57.6 (22.6) for the period from Emcitate "Managed Access Program" of MSEK 18.2 (5.7) during the quarter and MSEK 43.1 (21.9) during the period. In addition, revenue also include a milestone payment for a licensing agreement in Japan amounting to MSEK 14.5. The increase in revenue during the quarter is attributed both due to higher demand and regional variations in orders. Revenue in the comparative full year period previous year included forwarding of expenses related to PledOx to Solasia Pharma K.K. (Solasia) with an amount of MSEK 0.6.

Expenses

Operating expenses amounted to MSEK -115.7 (-83.9) during the quarter and MSEK -382.4 (-220.6) during the period. The project expenses amounted to MSEK -52.9 (-52.8) during the quarter and MSEK -193.5 (-136.3) during the period. The project expenses consisted of expenses due to Emcitate of MSEK -50.4 (-49.9) and Aladote of MSEK -2.5 (-2.8), during the quarter and MSEK -189.4 (-124.6) for Emcitate and MSEK -4.1 (-10.6) for Aladote during the period.

Employee costs amounted to MSEK -30.7 (-21.4) during the quarter and MSEK -84.0 (-52.0) during the period. The cost increase is due to the increase of number of employees ahead of the anticipated commercial launch of Emcitate. These include among others, work related to the ongoing and upcoming regulatory submissions in the EU and the USA. The costs also include participants' earnings in the employee stock option plans of MSEK -3.8 (-5.0) for the quarter and MSEK -8.0 (-8.8) for the period. Costs for the employee stock option plans will, to a certain extent, continue to vary with the share price development and do not impact cash flow.

Other external costs amounted to MSEK -26.0 (-6.4) during the quarter and MSEK -85.8 (-22.3) during the period. The increase is mainly due to higher consultancy costs related to Egetis' investments ahead of the planned commercial launch of Emcitate. These include among others, work related to the clinical studies and ongoing and upcoming regulatory submissions in the EU and the USA. Depreciation amounted to MSEK -0.9 (-0.7) for the quarter and MSEK -3.6 (-2.7) during the period. The depreciation during the period derives from amortization of licences with MSEK -1.1 (-1.1), depreciation of right-of-use assets with MSEK -2.4 (-1.5) and depreciation of inventories with MSEK -0.1 (-0.1). Other operating expenses amounted to MSEK -0.5 (-1.3) for the quarter and MSEK -4.6 (-1.1) for the period and consists of exchange rate differences from operating income and operating expenses.

Results

Operating results amounted to MSEK -83.1 (-78.2) for the quarter and MSEK -324.8 (-198.1) for the period. Net financial items amounted to MSEK -3.0 (0.4) for the quarter and MSEK -2.0 (4.3) for the period. Results from net financial items are primarily related interest rate income on company held cash deposits, interest cost on loan and revaluation of the convertible loan of some MSEK -2,7 (-) for the quarter and the period. Results after financial items amounted to MSEK -86.1 (−77.8) for the quarter and MSEK -326.8 (-193.8) for the period. Results per share before and after dilution amounted to SEK -0.3 (-0.4) for the quarter and SEK −1.3 (-1.0) for the period.

Financial position

Cash

Cash as of December 31, 2023, amounted to MSEK 303.3 (127.7).

Cash flow

Cash flow from operating activities amounted to MSEK -41.6 (-62.4) for the quarter and MSEK -278.4 (-173.5) for the period. Total Cash flow amounted to MSEK 223.6 (-62.8) for the quarter and MSEK 180.4 (-19.5) for the period. Cash flow from operating activities is driven by costs related to the ongoing clinical studies and the preparations ahead of the anticipated commercial launch of Emcitate.

Cash flow from investment activities amounted to MSEK 0.0 (-1.7) during the period. The figures in the comparative period previous year included payment of deferred purchase price for the acquisition of Rare Thyroid Therapeutics International AB (RTTI AB). Cash flow from financing activities amounted to MSEK 264.8 (-0.4) for the quarter and MSEK 458.9 (155.7) for the period and derives mainly from the capital markets transactions that were completed during January and October 2023.

Equity and equity ratio

As of December 31, 2023, equity amounted to MSEK 545.6 (506.2). Shareholders' equity per average number of shares amounted to SEK 2.1 (2.6), at the end of the period. The company's equity ratio was 72 (90) %.

Debts and receivables

As of December 31, 2023, non-current liabilities amounted to MSEK 110.8 (5.5). These consist of a long-term loan of MSEK 92.3 (-), a convertible loan of MSEK 11.1 (-), liabilities that derive from right of use liabilities according to IFRS 16 of MSEK 2.2 (1.1) and provisions for social security contributions relating to stock option plans of MSEK 5.1 (4.4). Current liabilities amount to MSEK 103.9 (49.4) of which other liabilities and accrued expenses amount to MSEK 69.8 (29.4), short-term loan MSEK 5.2 (-) and accounts payable amount to MSEK 28.7 (20.0). The increase in accrued expenses is related to provisions for discounts, determined annually. The provisions are estimated by the company based on industry practices, with final adjustment to be made after agreement with authorities upon market approval.

Investments in tangible and intangible assets

As of December 31, 2023, Intangible assets amounted to MSEK 409.1 (410.2). No significant investments were allocated to tangible assets during the period.

Shares

The number of shares as of December 31, 2023, were 292,571,459. The number of shares has increased with 42,982,331 shares as a result of the directed new share issue during October. The number of shareholders were 7,143 as of December 31, 2023. The 10 largest shareholders hold 65,6 % of outstanding shares. Egetis Therapeutics shares are listed on Nasdaq Stockholm's main market.

Stock option plan and warrant programs

Information regarding existing incentive programs

For information about current and previous employee stock option programs please see note 7.

Employees

Number of employees as of December 31, 2023, were 29 (17) persons, 17 women and 12 men (10 women and 7 men).

Parent company

The parent company's Revenue for the quarter amounted to MSEK - (-) and MSEK - (0.6) for the period. Revenue in the prior period were due to forwarding of expenses related to PledOx to Solasia. Other income for the quarter amounted to MSEK 32.5 (22.0) and MSEK 98.1 (53.6) for the period. Other income for the period consisted of MSEK 44.5 (27.7) management fees invoiced to the subsidiaries RTTI AB and Egetis Therapeutics US Inc., MSEK 49.1 (25.5) for forwarding of expenses to RTTI AB and MSEK 4.5 (0.4) as exchange rate gains.

Operating expenses amounted to MSEK -60.1 (-46.0) for the quarter and MSEK -177.3 (-117.4) for the period. The project expenses amounted to MSEK -17.8 (-17.7) for the quarter and MSEK -55.2 (-42.4) during the period.

The parent company's results amounted to MSEK -105.6 (-104.3) for the quarter and MSEK -325.9 (-194.5) for the period.

Financial assets amount to MSEK 435.0 (433.8). Long-term loan liabilities amount to MSEK 92.3 (-), convertible loan MSEK 11.1 (-) and other long-term liabilities MSEK 5.1 (-4.4).

Disposition of profit

The Board proposes that Egetis Therapeutics AB (publ) does not provide any dividend for the financial year 2023.

Consolidated statement of income

MSEK	2023 Oct-Dec	2022 Oct-Dec	2023 Jan-Dec	2022 Jan-Dec
Revenue				
Revenue	32.6	5.7	57.6	22.6
Other operating income	-	-	-	-
Total revenue	**32.6**	**5.7**	**57.6**	**22.6**
Operating expenses				
Costs of sales of goods	-4.7	-1.3	-11.0	-6.3
Project costs	-52.9	-52.8	-193.5	-136.3
Other external costs	-26.0	-6.4	-85.8	-22.3
Employee costs	-30.7	-21.4	-84.0	-52.0
Depreciation and impairment	-0.9	-0.7	-3.6	-2.7
Other operating expenses	-0.5	-1.3	-4.6	-1.1
Sum operating expenses	**-115.7**	**-83.9**	**-382.4**	**-220.6**
Operating results	**-83.1**	**-78.2**	**-324.8**	**-198.1**
Financial items				
Interest income and similar items	3.5	1.0	4.9	5.0
Interest expense and similar items	-3.8	-0.6	-4.2	-0.7
Revaluation of convertible right	-2.7	-	-2.7	-
Sum financial items	**-3.0**	**0.4**	**-2.0**	**4.3**
Results after financial net	**-86.1**	**-77.8**	**-326.8**	**-193.8**
Tax	-0.1	-	-0.1	-
Net loss for the period	**-86.3**	**-77.8**	**-326.9**	**-193.8**
Net earnings and comprehensive income is entirely attributable to parent company shareholders				
Share Data				
Number of shares at the end of period	292,571,459	214,589,128	292,571,459	214,589,128
Average number of shares during period, before dilution	287,899,467	214,589,128	256,752,282	194,238,210
Average number of shares during period, after dilution	290,098,106	215,390,155	260,011,478	194,238,210
Earnings per share before dilution, SEK	-0.3	-0.4	-1.3	-1.0
Earnings per share after dilution, SEK	-0.3	-0.4	-1.3	-1.0
Equity per average number of shares, SEK	1.9	2.4	2.1	2.6
Equity per average number of shares after dilution, SEK	1.9	2.4	2.1	2.6

Statement of comprehensive income

MSEK	2023 Oct-Dec	2022 Oct-Dec	2023 Jan-Dec	2022 Jan-Dec
Net loss for the period	**-86.3**	**-77.8**	**-326.9**	**-193.8**
Translation exchange rate differences	-0.2	-	-0.1	-
Comprehensive income for the period	**-86.5**	**-77.8**	**-327.0**	**-193.8**

Consolidated statement of financial position

MSEK	31/12/2023	31/12/2022
ASSETS		
Non-current assets		
Research and development costs	404.8	404.8
Licences	4.3	5.4
Right-of-use assets	4.3	2.6
Equipment	0.1	0.1
Financial non-current assets	0.8	0.8
Total non-current assets	**414.3**	**413.7**
Current assets		
Inventories	0.7	0.6
Accounts receivables	28.2	3.8
Other receivables	8.2	6.4
Prepaid expenses and accrued income	5.5	8.9
Cash and bank balance	303.3	127.7
Total current assets	**345.9**	**147.4**
Total assets	**760.2**	**561.1**

MSEK	31/12/2023	31/12/2022
Equity		
Share capital	15.4	11.3
Other capital contributions	1,780.0	1,428.4
Reserves	16.7	6.1
Accumulated loss including net loss	-1,266.5	-939.6
Total equity	**545.6**	**506.2**
Non-current liabilities		
Borrowing	103.4	-
Other non-current liabilities	2.2	1.1
Provisions	5.1	4.4
Total non-current liabilities	**110.8**	**5.5**
Current liabilities		
Accounts payable	28.7	20.0
Current tax liabilities	0.1	-
Borrowing	5.2	-
Other liabilities	6.8	5.7
Accrued expenses and deferred income	63.0	23.7
Total current liabilities	**103.9**	**49.4**
Total equity and liabilities	**760.2**	**561.1**

Consolidated statement of cash flows

MSEK	2023 Oct-Dec	2022 Oct-Dec	2023 Jan-Dec	2022 Jan-Dec
OPERATING ACTIVITIES				
Result after financial net	-86.1	-77.8	-326.8	-193.8
Adjustments for non-cash items	9.6	5.4	17.7	9.4
Tax paid	-0,1	-	-0,1	-
Cash flow from operating activities before changes in working capital	**-76.7**	**-72.4**	**-309.3**	**-184.4**
Cash flow from changes in working capital				
Increase/decrease in operating receivables	-9.1	-6.6	-22.9	-10.7
Increase/decrease in operating liabilities	44.1	16.6	53.8	21.6
Cash flow from changes in working capital	**35.0**	**10.1**	**30.9**	**10.9**
Cash flow from operating activities	**-41.6**	**-62.4**	**-278.4**	**-173.5**
INVESTING ACTIVITIES				
Acquisition of subsidiaries, net cash required	-	-	-	-1.7
Investment in financial assets	0.4	0.0	0.0	0.0
Purchase of property, plant and equipment	-	-	0.0	-
Cash flow from investing activities	**0.4**	**0.0**	**0.0**	**-1.7**
FINANCING ACTIVITIES				
New share issue	171.9	-	381.9	177.4
Cost new share issue	-12.2	-	-26.3	-12.6
Proceeds from borrowings	108.8	-	108.8	-
Repayment of loans	-3.0	-	-3.0	-7.5
Repayment of leases	-0.6	-0.4	-2.6	-1.6
Cash flow from financing activities	**264.8**	**-0.4**	**458.9**	**155.7**
Cash flow for the period	**223.6**	**-62.8**	**180.4**	**-19.5**
Balance at beginning of period	85.0	190.1	127.7	144.0
Change in cash	223.6	-62.8	180.4	-19.5
Exchange rate difference in cash	-5.3	0.4	-4.8	3.2
CASH BALANCE AT THE END OF THE PERIOD	**303.3**	**127.7**	**303.3**	**127.7**

Consolidated statement of changes in equity

MSEK	Share capital	Other capital contributions	Accumulated loss incl. net results for the period	Other reserves	Total equity
Opening balance 01/01/2023	**11.3**	**1,428.4**	**-939.6**	**6.1**	**506.2**
Share issue	4.1	377.8	-	-	381.9
Costs, Share issue	-	-26.3	-	-	-26.3
Comprehensive income for the period	-	-	-327.0	-	-327.0
Transactions with shareholders					
Issued warrants	-	-	-	3.4	3.4
Costs due to share-based payments of employee stock option plan	-	-	-	7.2	7.2
Closing balance 31/12/2023	**15.4**	**1,780.0**	**-1,266.5**	**16.7**	**545.6**
Opening balance 01/01/2022	**8.7**	**1,262.8**	**-745.8**	**1.3**	**527.0**
Rights issue	2.6	178.1	-	-	180.8
Costs, rights issue	-	-12.6	-	-	-12.6
Comprehensive income for the period	-	-	-193.8	-	-193.8
Transactions with shareholders					
Costs due to share-based payments of employee stock option plan	-	-	-	4.8	4.8
Closing balance 31/12/2022	**11.3**	**1,428.4**	**-939.6**	**6.1**	**506.2**

Change in share capital and number of shares

Event	Change in number of shares	Change in share capital, SEK	Total number of shares	Total share capital, SEK
Opening balance 01/01/2023	**-**	**-**	**214,589,128**	**11,294,169**
Share issue 01/26/2023	35,000,000	1,842,106	249,589,128	13,136,275
Share issue, 10/10/2023	42,982,331	2,262,229	292,571,459	15,398,504
Closing balance 12/31/2023	**-**	**-**	**292,571,459**	**15,398,504**

Consolidated key ratios

The key ratios below are useful to those who read the financial statements and a complement to other performance targets in evaluating strategic investment implementation and the Group's ability to achieve financial goals and commitments.

MSEK	2023 Jan-Dec	2022 Jan-Dec
Equity	545.6	506.2
Equity ratio	72%	90%
Number of shares at the end of the period	292,571,459	214,589,128
Average number of shares during the period	256,752,282	194,238,210
Average number of shares during the period after dilution	260,011,478	194,238,210
Share Data		
Earnings per share, SEK	-1.3	-1.0
Earnings per share after dilution, SEK	-1.3	-1.0
Cash flow from operating activities, before dilution, SEK	-1.1	-0.9
Equity per average number of shares, SEK	2.1	2.6
Equity per average number of shares after dilution, SEK	2.1	2.6
Dividend	-	-
Average number of employees	27	15

*Effect from dilution is not considered when result is negative.

Parent company - income statement

MSEK	2023 Oct-Dec	2022 Oct-Dec	2023 Jan-Dec	2022 Jan-Dec
Revenue				
Revenue	-	0.0	-	0.6
Other operating income	32.5	22.0	98.1	53.6
	32.5	**22.0**	**98.1**	**54.2**
Operating expenses				
Project costs	-17.8	-17.7	-55.2	-42.4
Other external costs	-12.4	-6.7	-43.7	-22.4
Employee costs	-26.0	-21.4	-73.9	-52.0
Depreciation and impairment	0.0	0.0	-0.1	-0.1
Other operating expenses	-3.9	-0.2	-4.4	-0.6
Sum operating expenses	-60.1	-46.0	-177.3	-117.4
Operating results	**-27.6**	**-24.0**	**-79.2**	**-63.2**
Financial items				
Interest income and similar items	3.4	-0.3	4.8	3.7
Interest expense and similar items	-3.7	0.0	-3.9	0.0
Net result of financial transactions	-2.7	-	-2.7	-
Sum financial items	-3.0	-0.3	-1.8	3.7
Results after financial net	**-30.6**	**-24.3**	**-80.9**	**-59.5**
Appropriations	-75.0	-80.0	-245.0	-135.0
Tax	-	-	-	-
Net loss for the period	**-105.6**	**-104.3**	**-325.9**	**-194.5**

Parent company - balance sheet

MSEK	31/12/2023	31/12/2022
ASSETS		
Non-current assets		
Equipment	0.1	0.1
Financial non-current assets	435.0	433.8
Total non-current assets	**435.0**	**433.9**
Current assets		
Receivables from Group companies	0.5	0.1
Other receivables	0.0	0.6
Prepaid expenses and accrued income	9.3	3.8
Cash and bank balance	271.6	120.0
Total current assets	**281.5**	**124.4**
Total assets	**716.5**	**558.3**

MSEK	31/12/2023	31/12/2022
Equity		
Restricted Equity		
Share capital	15.4	11.3
Non-restricted equity		
Share premium reserve	830.9	673.8
Reserves	16.7	6.1
Net loss for the period	-325.9	-194.5
Total equity	**537.1**	**496.7**
Non-current liabilities		
Borrowing	103.4	-
Provisions	5.1	4.4
Total non-current liabilities	**108.6**	**4.4**
Current liabilities		
Liabilities to group company	38.1	33.1
Accounts payable	5.5	7.8
Borrowing	5.2	-
Other liabilities	4.3	3.9
Accrued expenses and deferred income	17.7	12.4
Total current liabilities	**70.9**	**57.2**
Total equity and liabilities	**716.5**	**558.3**

Notes

Note 1 - Accounting principles

Egetis applies International Financial Reporting Standards (IFRS) as adopted by the EU. This report is prepared in accordance with IAS 34 Interim Financial Reporting and the Annual Accounts Act and should be read together with the Egetis consolidated financial statements for the year ended December 31, 2022. The interim report does not include all disclosures that would otherwise be required in a complete set of financial statements. Applied accounting principles and calculation methods are the same as in the latest annual report for 2022. Some amendments to existing standards became applicable from January 1, 2023, however none of these have a material impact on the consolidated financial statements or accounting policies. The parent company and the Group's accounting currency is SEK. All the numbers in this interim report are, if nothing else is stated, presented in million SEK.

The preparation of interim reports requires certain critical accounting estimates to be made. Furthermore, company management is required to make assessments when applying accounting principles. During the year assessed industry standard rebate scheme which are settled on an annual basis and with final settlement to be made after agreement with authorities upon market approval been added. These assessments are based on the judgement from external expertise. Final discounts given are subject to annual calculation and adjustment, which may require a revision of the reported revenues. Additionally, financial liabilities related to loans have been added and initially recognized at fair value, including transaction costs. After the initial recognition, the liabilities are measured at amortized cost using the effective interest method.

Embedded derivatives, meeting the definition of a derivative and included in the terms of another contract, the host contract, have also been added. The agreement, the host contract, and the embedded derivative form a hybrid instrument. Embedded derivatives have the effect that some or all cash flows in the composite contract vary similarly to a stand-alone derivative. Derivatives embedded in debt contracts must be separated from the host contract and measured as stand-alone derivatives when their economic characteristics and risks are not closely related to the host contract. A separated embedded derivative is valued and accounted for according to the principles for stand-alone derivatives.

The components of convertible bonds issued by the group are classified separately as financial liabilities and embedded derivative liabilities in accordance with the terms and definitions of a financial liability and a derivative. The convertible is issued in euro, and therefore, the conditions for equity classification are not met. The conversion option is classified as a derivative, valued at inception using widely accepted option pricing models (Black Scholes). The option is subsequently revalued at fair value through the income statement.

Transaction costs related to the derivative part are directly recognized in the income statement. Transaction costs related to the debt part are included in the recognized value of the debt and amortized over the term of the convertible bonds using the effective interest method. This includes the fair value of the derivative at inception and the allocated portion of warrants.

The convertible part of the loan is an issued call option on own shares valued at fair value through the income statement. The option is valued using the Black Scholes model. The valuation falls under level 3 in the fair value hierarchy. Level 3 fair value measurements are those derived from valuation techniques that include inputs for the asset or liability that are not based on observable market data (unobservable inputs), in this case, volatility.

See the Group's accounting principles in the annual report 2022 regarding more information on estimates and assessments.

Parent company

The parent company Egetis Therapeutics AB (publ) prepares financial reports in accordance with the Swedish Financial Reporting Board's recommendation RFR 2 Accounting for Legal Entities and the Swedish Annual Accounts Act. The parent company applies the exception from application of IFRS 16 Leases.

Operating risks

All business operations involve risk. Risks may be company specific or due to events in the external environment and may affect a certain industry or market. The group is, among others, exposed to the following operational and financial risks.

Operational risks:
Pharmaceutical development, Manufacturing, Regulatory, Commercialization, Competition and Market Acceptance and Intellectual property.

Financial risks:
Foreign currency, Need of working capital, General market risk, Credit and Interest rate risks.

A more detailed description of the Group's risk exposure is included in Egetis 2022 Annual Report, *Risks and Risk Management* section and Note 3. Changes in the group's risk exposure during 2023 include a decrease in liquidity risk as the group's liquidity reserve on the balance sheet date amounts to 303.3 million SEK, consisting of cash and cash equivalents. In addition to this, there are guaranteed additional facilities of 15 million EUR, which are, however, conditional on the balance sheet date, and the conditions for utilization have not been met yet.

At the same time, interest rate risk has increased as the group is exposed to variable interest rate risk in its borrowing, tied to the ECB's variable base rate (Main Refinancing Operations Interest Rate, MRO). Additionally, there is an increased currency risk as the group is exposed to currency risk related to loan commitments in euros.

External risk factors

Egetis Therapeutics is dependent on the efficient and uninterrupted operation of various IT systems to run its business. A significant breakdown or other disruption in the IT systems (for example as a result of a virus attack or network congestion attacks) can affect the ability to conduct business in general and can lead to delays and increased costs in the Company's research and development work.

There is a risk that the Company, as a result of such as viral pandemics, will not succeed in recruiting participants for its clinical studies, either because participants do not want, or due to restrictions should not, visit hospitals to avoid infection. There is also a risk that new variants of different microorganisms will lead to lockdowns in Sweden or in other countries, which could mean that the Company or its partners cannot conduct research and development work according to the existing clinical development plan. There is also a risk that caregivers need to allocate resources to meet the effects of different pandemics, which can lead to limited resources to participate in the Company's clinical trials.

Continued and/or escalating tension between Russia and Ukraine led to Russia's full-scale military invasion of Ukraine, middle eastern conflicts and current inflationary situation in the society could have a significant

negative impact on the global macroeconomic situation and the Swedish economy. It could result in the Company or its partners not being able to conduct R&D efforts according to plan.

A more detailed description of the Group's risk exposure is included in Egetis 2022 Annual Report, *Risks and Risk Management* section and Note 3. Changes in the group's risk exposure during 2023 compared to 2022 are outlined above in the section "Operating risks".

Note 2 – Additional information

Other information in accordance with IAS 34.16A are found on the pages before the income statement and statement of comprehensive income. For information on earnings, cash flow and financial position, see page 10. For events after the period, see page 1.

Note 3 – Segments

The Group applies segment reporting with mainly two independent development areas, Emcitate and Aladote. The highest executive decision-maker in the Company allocates the Company's resources between these two R&D projects. The Aladote project has been parked since June 2023. Revenue for Emcitate is attributable to the "*Named Patient Use*" use of the drug candidate.

Revenue and expenses attributable to Emcitate and Aladote are reported below.

2023 Oct-Dec MSEK	Emcitate	Aladote	Common*	Sum
Revenue	32.6	-	-	**32.6**
Costs of sales of goods	-4.7	-	-	**-4.7**
Project costs	-50.4	-2.5	-	**-52.9**
Other	-	-	-58.1	**-58.1**
Operating results	**-22.5**	**-2.5**	**-58.1**	**-83.1**
Net financial items				**-3.0**
Pretax profit				**-86.1**

2022 Oct-Dec MSEK	Emcitate	Aladote	Common*	Sum
Revenue	5.7	-	0.0	**5.7**
Costs of sales of goods	-1.3	-	-	**-1.3**
Project costs	-49.9	-2.8	-	**-52.8**
Other	-	-	-29.8	**-29.8**
Operating results	**-45.5**	**-2.8**	**-29.8**	**-78.2**
Net financial items				**0.4**
Pretax profit				**-77.8**

2023 Jan-Dec MSEK	Emcitate	Aladote	Common*	Sum
Revenue	57.6	-	-	**57.6**
Costs of sales of goods	-11.0	-	-	**-11.0**
Project costs	-189.4	-4.1	-	**-193.5**
Other	-	-	-177.9	**-177.9**
Operating results	**-142.9**	**-4.1**	**-177.9**	**-324.8**
Net financial items				**-2.0**
Pretax profit				**-326.8**

2022 Jan-Dec MSEK	Emcitate	Aladote	Common	Sum
Revenue	21.9	-	0.6	**22.6**
Costs of sales of goods	-6.3	-	-	**-6.3**
Project costs	-124.6	-10.6	-1.1	**-136.3**
Other	-	-	-78.0	**-78.0**
Operating results	**-109.0**	**-10.6**	**-78.5**	**-198.1**
Net financial items				**4.3**
Pretax profit				**-193.8**

*) Revenue and project costs attributable to the parked PledOx project are provided in the "Common" column in the comparative period.

Turnover by type of revenue

MSEK	2023 Oct-Dec	2022 Oct-Dec	2023 Jan-Dec	2022 Jan-Dec
Re-invoicing of costs to Solasia	-	0.0	-	0.6
License sales	14.5	-	14.5	-
Sales of goods	18.2	5.7	43.1	21.9
Total	**32.6**	**5.7**	**57.6**	**22.6**

Note 4 – Contingent liabilities

Egetis has a contractual obligation, on future net sales from Emcitate, to provide royalty payments to the previous owners of Rare Thyroid Therapeutics International AB and Erasmus Medical Center corresponding to a low double-digit percentage of net sales of the product.

Note 5 – Related party transactions

Peder Walberg has been providing consultancy services to the company, invoicing MSEK 1.9 (1.7) during the period.

Note 6 - Borrowing

MSEK	31/12/2023	31/12/2022
Convertible loan	-11.1	-
Borrowing - Non-current	-92.3	-
Borrowing - Current	-5.2	-
Total	**-108.6**	**-**

Loan

During the fourth quarter 2023, a combined financing was carried out, consisting of a directed share issue of approximately 172 million SEK and a debt financing of about 290 million SEK, aimed at funding the ongoing development towards the application for the first approved treatment for MCT8 deficiency patients.
The debt financing in Euros is divided into two parts, 10 million euros ("Tranche A") and 15 million euros ("Tranche B"), which will be made available provided that the Company meets certain conditions, including those related to the phase III study (ReTRIACt) for Emcitate for Tranche B. The interest for the tranches is based on the ECB's base rate (MRO) plus a margin. An interest rate discount will be applied upon FDA approval of Emcitate.

Tranche A was utilized on November 30, 2023 and matures on April 1, 2027. Tranche B is available for utilization until September 30, 2024 and matures on December 1, 2027.

Warrants

As part of the Debt Financing, the lender will also receive warrants entitling them to subscribe for shares in the Company. The total number of warrants to be issued to the lender will depend on the utilization of Tranche A and Tranche B. Upon full utilization of Tranche A and Tranche B, the lender will be entitled to 1,090,977 warrants for Tranche A and 1,636,464 warrants for Tranche B, equivalent to 0.9 percent of the total number of shares in the Company on a fully diluted basis. The exercise price for the warrants is 4.26 SEK. The warrants will be subject to customary recalculation terms and shall be exercisable prior to the tenth anniversary of the grant date.
In connection with the utilization of Tranche A, 1,090,977 warrants were issued with an estimated market value of 3.4 million SEK, which is reported as an increase in the equity of the parent company and the group.

Convertible Loan

A portion of Tranche A is a convertible loan of 3 million euros, which can be converted into shares in the Company at a conversion rate of approximately 0.5133 euros per share. Repayment of the convertible loan shall be made no later than April 1, 2027, unless conversion occurs before then. The convertible loan, which grants a right but not an obligation to convert the loan into shares, is denominated in euros and, as indicated in note 1,

the criteria for accounting for the convertible as an equity instrument are not met. Therefore, the conversion option is classified as a derivative and is remeasured continuously at fair value through the income statement. This remeasurement has no impact on cash flows.

Note 7 – Employee Stock Option Plan

During the twelve months of 2023, the average share price exceeded the exercise price of the majority of the employee stock option plan (ESOP) 2022 why a dilution effect is reported in the number of shares after dilution. However, as earnings per share are negative, no dilution is reported in the key ratio earnings per share after dilution. As of December 31, 2023, the company has four ESOPs outstanding. Full utilization of the granted stock options would increase the number of shares in the company by 23,350,548.

Employee Stock option plan 2023

The 2023 Annual General Meeting resolved on a 2023/2026 stock option plan of 9,000,000 stock options for employees at Egetis Therapeutics, of which 8,491,276 were granted to employees and key consultants, as of December 31, 2023. The CEO and the rest of the management team (eight individuals) were granted 1,313,869 and 4,783,285 employee stock options, respectively. To ensure the delivery of shares to participants in the incentive plans as well as to cover social security contributions when the share awards and employee options are exercised, the Parent Company has issued 10,350,000 warrants to its subsidiary Egetis Therapeutics Incentive AB.

The ESOP is implemented for employees and key consultants. The options were allotted free of charge to participants of the program. The options have a three-year vesting period calculated from the allotment date, provided that, with customary exceptions, the participants remain as employees of, or continue to provide services to Egetis. Once the options are vested, they can be exercised within a six-month period. Each vested option entitles the holder to acquire one share in Egetis at a predetermined price. The price per share is to be equivalent to 120% of the weighted average price that the company's shares were traded for on Nasdaq Stockholm during the ten trading days preceding the allotment date, however, the price per share shall not be lower than SEK 7.2. The options have, at the time of issue, been valued according to the Black & Scholes valuation models. The exercise price is SEK 7.2 per option.

Employee Stock option plan 2022

The 2022 Annual General Meeting resolved on a 2022/2026 stock option plan of 7,300,000 stock options for employees at Egetis Therapeutics, of which 7,109,272 were granted to employees and key consultants, as of March 31, 2023. The CEO and the rest of the management team (eight individuals) were granted 1,430,463 and 4,033,776 employee stock options, respectively. To ensure the delivery of shares to participants in the incentive plans as well as to cover social security contributions when the share awards and employee options are exercised, the Parent Company has issued 9,592,200 warrants to its subsidiary Egetis Therapeutics Incentive AB.

The ESOP is implemented for employees and key consultants. The options were allotted free of charge to participants of the program. The options have a three-year vesting period calculated from the allotment date, provided that, with customary exceptions, the participants remain as employees of, or continue to provide services to Egetis. Once the options are vested, they can be exercised within a one-year period. Each vested option entitles the holder to acquire one share in Egetis at a predetermined price. The price per share is to be equivalent to 120% of the weighted average price that the company's shares were traded for on Nasdaq Stockholm during the ten trading days preceding the allotment date. The options have, at the time of issue, been

valued according to the Black & Scholes valuation models. The exercise prices are in the interval of SEK 4.22-7.15 per option.

Employee Stock option plan 2021

The 2021 Annual General Meeting resolved on a 2021/2025 stock option plan for employees at Egetis Therapeutics AB. The number of outstanding and granted stock options are 4,850,000. To ensure the delivery of shares to participants in the Company's incentive plans as well as to cover social security contributions when the share awards and employee options are exercised, the Parent Company has issued 6,571,000 warrants to its subsidiary Egetis Therapeutics Incentive AB. After re-calculation, according to the terms and conditions for the ESOP, for the May 2022 rights issue, every stock option is eligible to 1,02 shares and the updated exercise price is SEK 9.33 per option.

Employee Stock option plan 2020

The 2020 Annual General Meeting resolved on a 2020/2024 stock option plan for employees at PledPharma (previous company name for Egetis Therapeutics AB). The number of granted stock options are 2,900,000. To ensure the delivery of shares to participants in the Company's incentive plans as well as to cover social security contributions when the share awards and employee options are exercised, the Parent Company has issued 3,942,600 warrants to its subsidiary Egetis Therapeutics Incentive AB. After re-calculation, according to the terms and conditions for the ESOP, for the November 2020 and May 2022 rights issues, the numbers of shares each stock option is entitled to is 1,0404 shares and the updated exercise price is SEK 11,71 per option.

Changes in outstanding employee stock options and warrants to lenders during 2023

	Option plan 2023/2026	Option plan 2022/2026	Option plan 2021/2025	Option plan 2020/2024	Warrants to lender	Total number of outstanding options
Number of outstanding options 01/01/2023	**-**	**7,300,000**	**5,000,000**	**2,900,000**	**-**	**15,200,000**
Number of granted options during the period	8,706,203	0	0	-	1,090,977	**9,797,180**
Number of forfeited options during the period	-214,927	-190,728	-150,000	-	-	**-555,655**
Number of outstanding options 31/12/2023	**8,491,276**	**7,109,272**	**4,850,000**	**2,900,000**	**1,090,977**	**24,441,525**

Note 8 –Key ratios definitions

Ratios that have been calculated according to IFRS

Earnings per share. Net income divided by average number of shares before dilution.

Number of shares at end of period. The number of outstanding shares before dilution at the end of the period.

Number of shares after dilution. The number of issued shares after dilution effect of potential shares at end of period.

Average number of shares during the period. Average number of outstanding shares before dilution for the period.

Average number of shares during the period after dilution. Average number of issued shares after dilution effect of potential shares.

Project costs Refer to external costs that are directly attributable to the Group's costs regarding research and development of drug candidates.

Ratios that have not been calculated in accordance with IFRS

The company defines the below ratios as follows.

Equity ratio, % The period's closing equity divided by the period's closing balance sheet. The Company uses the alternate Equity ratio as it shows the proportion of total assets represented by shareholders' equity and has been included to allow investors to assess the Company's capital structure.

Cash flow from operations per share. Cash flow from operating activities divided by the average number of shares outstanding at the end of the period. The Company uses the alternate key figure Cash flow from operations per share because the Company believes that the key ratio gives investors a better understanding of the Company's cash flow in relation to its number of shares adjusted for changes in the number of shares outstanding during the period.

Equity per share. Equity divided by number of shares outstanding at the end of the period. Outstanding stock options and warrants are only considered if they are "in the money". The Company uses the alternate key ratio equity per share because the Company believes that the key ratio gives investors a better understanding of the historical return per share adjusted for changes in the number of shares outstanding during the period.

Number of employees (average). The average number of employees at the end of each period.

		2023 Jan-Dec	2022 Jan-Dec
A	Equity, MSEK	545.6	506.2
B	Balance sheet total, MSEK	760.2	561.1
A/B	**Equity ratio %**	**72%**	**90%**
A	Net result, MSEK	-327.0	-193.8
B	Equity, MSEK	545.6	506.2
A/B	**Return on equity, %**	**neg.**	**neg.**
A	Cash flow from operating activities, MSEK	-278.4	-173.5
B	Average number of shares under the period, before dilution, thousand	256,752	194,238
A/B	**Cash flow from operating activities per shares, SEK**	**-1.1**	**-0.9**
A	Equity, MSEK	545.6	506.2
B	Average number of shares at the end of the period before dilution, thousand	256,752	194,238
A/B	**Equity per average number of shares before dilution, SEK**	**2.1**	**2.6**
A	Equity, MSEK	545.6	506.2
B	Average number of shares at the end of the period after dilution, thousand	260,011	194,238
A/B	**Equity per average number of shares after dilution, SEK**	**2.1**	**2.6**

Other information

Next reports

Interim report January 1- March 31: May 3, 2024
Annual General Meeting: May 6, 2024
Half-year report January 1- June 30: August 22, 2024
Interim report January 1- September 30: November 8, 2024

This report, and further information is available on the website, www.egetis.com
This report has not been reviewed by the Company's auditor. This is a translation of the Swedish interim report.

For further information, please contact:

Nicklas Westerholm, CEO
E-mail: nicklas.westerholm@egetis.com

Yilmaz Mahshid, CFO
E-mail: yilmaz.mahshid@egetis.com

This information is such information as Egetis Therapeutics AB (publ) is obliged to disclose in accordance with EU market abuse regulation and the Securities Markets Act. The information was submitted, through the above contact persons, for publication on February 22, 2024, at 7.00 am (CET).

Egetis Therapeutics AB (publ)
Klara Norra kyrkogata 26, 111 22 Stockholm, Sweden
Org.nr. 556706-6724 Phone: +46(0)8-679 72 10
www.egetis.com

Analysts who follow Egetis Therapeutics

ABGSC: Alexander Krämer
Bryan, Garnier & Co: Alex Cogut
Carnegie: Arvid Necander
Handelsbanken: Mattias Häggblom & Suzanna Queckbörner
Pareto Securities: Chien-Hsun Lee
Redeye: Fredrik Thor
Rx Securities: Joseph Hedden

Certification

This Year-End report for January-December 2023 period provides a true and fair overview of the parent's and group's business activities, financial position, and results of operations, and describes significant risks and uncertainties to which the companies in the group are exposed.

Stockholm, February 22, 2024

Thomas Lönngren	Mats Blom
Chairman of the board	Board member
Gunilla Osswald	Elisabeth Svanberg
Board member	Board member
Peder Walberg	Behshad Sheldon
Board member	Board member

Nicklas Westerholm

CEO